Mushrooms, tumors, and immunity

Proceedings of the Society for Experimental Biology and Medicine

Volumn 221, Issue 4, 1999, Pages 281-293

  Borchers, Andrea T ^a   Stern, Judith S ^a   Hackman, Robert M ^a   Keen, Carl L ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; GRIFOLAN; LENTINAN; POLYSACCHARIDE; SCHIZOPHYLLAN; SCLEROTINIA SCLEROTIORUM EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; FOOD INTAKE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MACROPHAGE; MOUSE; MUSHROOM; NONHUMAN; NUTRITIONAL SCIENCE; SHORT SURVEY; T LYMPHOCYTE;

ANIMALIA; BASIDIOMYCOTA; GRIFOLA FRONDOSA; LENTINULA EDODES; LENTINUS; MURINAE; SCHIZOPHYLLUM COMMUNE; SCLEROTINIA SCLEROTIORUM;

EID: 0032868925     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.1999.d01-86.x     Document Type: Short Survey

References (120)

1. Kaul TN. Introduction to Mushroom Science (Systematics). Enfield, NH: Science Publishers, Inc., 1997.
2. Jong SC, Birmingham JM. Medicinal benefits of the mushroom Ganoderma. Adv Appl Microbiol 37:101-134, 1992.
3. Zhou ZY, Jin HD. Clinical Manual of Chinese Herbal Medicine and Acupuncture. New York, NY: Churchill Livingstone, 1997.
4. Chang S-T, Miles PG. The nutritional attributes and medicinal value of edible mushrooms. In: Chang S-T, Miles PG, Eds. Edible Mushrooms and Their Cultivation. Boca Raton, FL: CRC Press, Inc., pp27-40, 1989.
5. Breene WM. Nutritional and medicinal value of specialty mushrooms. J Food Protect 53:883-894, 1990.
6. Miles PG, Chang S-T. Medicinal components of mushrooms. In: Miles PG, Chang S-T, Eds. Mushroom Biology: Concise Basics and Current Developments. River Edge, NJ: World Scientific, pp107-118, 1997.
7. Mizuno T, Saito H, Nishitoba T, Kawagishi H. Antitumor-active substances from mushrooms. Food Rev Int 11:23-61, 1995.
8. Chang S-T, Miles PG. Edible Mushrooms and Their Cultivation. Boca Raton, FL: CRC Press, Inc., 1989.
9. Miles PG, Chang S-T. Mushroom Biology: Concise Basics and Current Developments. River Edge, NJ: World Scientific, 1997.
10. Chang R. Functional properties of edible mushrooms. Nutr Rev 54:S91-S93, 1996.
11. Chang S-T, Buswell JA. Mushroom nutriceuticals. World J Microbiol Biotechnol 12:473-476, 1996.
12. Mizuno T. Bioactive biomolecules of mushrooms: Food function and medicinal effect of mushroom fungi. Food Rev Int 11:7-21, 1995.
13. Nanba H, Mori K, Toyomasu T, Kuroda H. Antitumor action of Shiitake (Lentinus edodes) fruit bodies orally administered to mice. Chem Pharm Bull 35:2453-2558, 1987.
14. Nanba H, Kuroda H. Antitumor mechanisms of orally administered Shiitake fruit bodies. Chem Pharm Bull 35:2459-2464, 1987.
15. Kurashige S, Akuzawa Y, Endo F. Effects of Lentinus edodes, Grifola frondosa, and Pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolinitrosoamine. Immunopharmacol Immunotoxicol 19:175-183, 1997.
16. Toth B, Erickson J. Cancer induction in mice by feeding of the fresh uncooked cultivated mushroom of commerce Agaricus bisporus. Cancer Res 46:4007-4011, 1986.
17. Shephard SE, Gunz D, Schlatter C. Genotoxicity of agaritine in the lac1 transgenic mouse mutation assay: Evaluation of the health risk of mushroom consumption. Food Chem Toxicol 33:257-264, 1995.
18. Toth B, Erickson J, Gannett P. Lack of carcinogenesis superfluous by the baked mushroom Agaricus bisporus in mice: Different feeding regimen. In Vivo 11:227-232, 1997.
19. Toth B, Gannett P, Visek WJ, Patil K. Carcinogenesis studies with the lyophilized mushroom Agaricus bisporus in mice. In Vivo 12:239-244, 1998.
20. Matsumoto K, Ito M, Yagyu S, Ogino H, Hirono I. Carcinogenicity examination of Agaricus bisporus, edible mushroom, in rats. Cancer Lett 58:87-90, 1991.
21. Nanba H, Kuroda H. Potentiation of host-mediated antitumor activity by orally administered mushroom (Agaricus bispora) fruit bodies. Chem Pharm Bull 36:1437-1444, 1988.
22. Misaki A, Kakuta M. Kikurage (Tree-ear) and Shirokikurage (White Jelly leaf): Auricularia auricula and Tremella fuciformis. Food Rev Int 11:211-218, 1995.
23. Kiho T, Ukai S. Tochukaso (Semitake and others), Cordyceps species. Food Rev Int 11:231-234, 1995.
24. Zhuang C, Mizuno T. Niohshimeji, Tricholoma giganteum: Antitumor-active heteroglycans. Food Rev Int 11:197-202, 1995.
25. Misaki A, Kishida E. Straw mushroom, Fukurotake, Volvariella volvacea. Food Rev Int 11:219-223, 1995.
26. Mizuno T, Wang G, Zhang J, Kawagishi H, Nishitoba T, Li J. Reishi, Ganoderma lucidum and Ganoderma tsugae: Bioactive substances and medicinal effects. Food Rev Int 11:151-166, 1995.
27. Mizuno T. Shiitake, Lentinus edodes: Functional properties for medicinal and food purposes. Food Rev Int 11:111-128, 1995.
28. Kerékgyártó C, Virág L, Tankó L, Chihara G, Fachet J. Strain differences in the cytotoxic activity and TNF production of murine macrophages stimulated by lentinan. Int J Immunopharmacol 18:347-353, 1996.
29. Abel G, Szöllösi J, Chihara G, Fachet J. Effect of lentinan and mannan on phagocytosis of fluorescent latex microbeads by mouse peritoneal macrophages: A flow cytometric study. Int J Immunopharmacol 11:615-621, 1989.
30. Abel G, Szöllosi J, Chihara G, Fachet J. Effect of lentinan on pinocytosis in mouse peritoneal macrophages and the murine macrophage cell line C4MØ in vitro. Int J Immunopharmacol 8:919-924, 1986.
31. Fruehauf JP, Bonnard GD, Herberman RB. The effect of lentinan on production of interleukin-1 by human monocytes. Immunopharmacology 5:65-74, 1982.
32. Adachi Y, Ohno N, Ohsawa M, Oikawa S, Yadomae T. Change of biological activities of (1→3)-β-D-glucan from Grifola frondosa upon molecular weight reduction by heat treatment. Chem Pharm Bull 38:477-481, 1990.
33. Adachi Y, Okazaki M, Ohno N, Yadomae T. Enhancement of cytokine production by macrophages stimulated with (1→3)-β-D-glucan, grifolan (GRN), isolated from Grifola frondosa. Biol Pharm Bull 17:1554-1560, 1994.
34. Ohno N, Iino K, Takeyama T, Suzuki I, Sato K, Oikawa S, Miyazaki T, Yadomae T. Structural characterization and antitumor activity of the extracts from matted mycelium of cultured Grifola frondosa. Chem Pharm Bull 33:3395-3401, 1985.
35. Ohno N, Adachi Y, Suzuki I, Sato K, Oikawa S, Yadomae T. Characterization of the antitumor glucan obtained from liquid-cultured Grifola frondosa. Chem Pharm Bull 34:1709-1715, 1986.
36. Ohno N, Egawa Y, Hashimoto T, Adachi Y, Yadomae T. Effect of β-glucans on the nitric oxide synthesis of peritoneal macrophage (sic) in mice. Biol Pharm Bull 19:608-612, 1996.
37. Sakurai T, Ohno N, Suzuki I, Yadomae T. Effect of soluble fungal (1-3)-β-D-glucan obtained from Sclerotinia sclerotiorum on alveolar macrophage activation. Immunopharmacology 30:157-166, 1995.
38. Mashiba H, Matsunaga K. In vitro activation of human adherent cells by a glucan, schizophyllan. Jpn J Exp Med 53:195-198, 1983.
39. Hamuro J, Röllinghoff M, Wagner H. Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the β(1→3) glucan-type lentinan and its analogs. Immunology 39:551-559, 1980.
40. Ladányi A, T'már J, Lapis K. Effect of lentinan on macrophage cytotoxicity against metastatic tumor cells. Cancer Immunol Immunother 36:123-126, 1993.
41. Herlyn D, Kaneko Y, Powe J, Aoki T, Koprowski H. Monoclonal antibody-dependent murine macrophage-mediated cytotoxicity against human tumors is stimulated by lentinan. Jap J Cancer Res (Gann) 76:37-42, 1985.
42. Suzuki M, Arika T, Amemiya K, Fujiwara M. Cooperative role of T lymphocytes and macrophages in antitumor activity of mice pretreated with schizophyllan (SPG). Jpn J Exp Med 52:59-65, 1982.
43. Matsuo T, Arika T, Mitani M, Komatsu N. Pharmacological and toxicological studies of a new antitumor polysaccharide, schizophyllan. Arzneimittelforsch/Drug Res 32:647-656, 1982.
44. Ohno N, Hayashi M, Suzuki I, Oikawa S, Sato K, Suzuki Y, Yadomae T. Effect of activation or blockade of the phagocytic system on the antitumor activity of grifolan. Chem Pharm Bull 34:4377-4381, 1986.
45. Ohno N, Asada N, Adachi Y, Yadomae T. Enhancement of LPS triggered TNF-α (tumor necrosis factor-α) production by (1→α)-β-D-glucans in mice. Biol Pharm Bull 18:126-133, 1995.
46. Nono I, Ohno N, Masuda A, Oikawa S, Yadomae T. Oxidative degradation of an antitumor (1→3)-β-D-glucan, grifolan. J Pharmacobiodyn 14:9-19, 1991.
47. Adachi Y, Ohno N, Yadomae T. Activation of murine Kupffer cells by administration with gel-forming (1→3)-β-D-glucan from Grifola frondosa. Biol Pharm Bull 21:278-283, 1998.
48. Takeshita K, Hayashi S, Tani M, Kando F, Saito N, Endo M. Monocyte function associated with intermittant lentinan therapy after resection of gastric cancer. Surg Oncol 5:23-28, 1996.
49. Hamuro J, Chihara G. Lentinan, a T-cell-oriented immunopotentiator: Its experimental and clinical applications and possible mechanism of immune modulation. In: Fenichel RL, Chirigos MA, Eds. Immune Modulating Agents and Their Mechanisms. New York: Marcel Dekker, pp409-436, 1985.
50. Toko T, Fujimoto S. Augmentation of antitumor immunity in low-responder mice by various biological response modifiers: Analysis of effector mechanism. Jpn J Cancer Res 80:1212-1219, 1989.
51. Suzuki M, Iwashiro M, Takatsuki F, Kuribayashi K, Hamuro J. Reconstitution of antitumor effects of lentinan in nude mice: Roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor. Jpn J Cancer Res 85:409-417, 1994.
52. Suzuki M, Kikuchi T, Takatsuki F, Hamuro J. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells. Cancer Immunol Immunother 38:1-8, 1994.
53. Hamuro J, Takatsuki F, Suga T, Kikuchi T, Suzuki M. Synergistic antimetastatic effects of lentinan and interleukin 2 with pre- and postoperative treatments. Jpn J Cancer Res 85:1288-1297, 1994.
54. Taguchi T, Aoki T, Furue H, Mazima H. Phase I and II studies of lentinan. In: Aoki T, Uryshizaki I, Tsubura E, Eds. Manipulation of Host Defense Mechanisms. Princeton, NJ: Excerpta Medica, pp259-266, 1981.
55. Taguchi T, Kaneko Y. Lentinan: An overview of experimental and clinical studies of its action against cancer. In: Umshizaki I, Aoki T, Tsubura E, Eds. Host Defense Mechanisms Against Cancer. Princeton, NJ: Excerpta Medica, pp221-229, 1981.
56. Taguchi T, Furue H, Hattori T, Kondo T, Kimura T, Itoh I, Ogawa N. Cooperative phase studies of lentinan. In: Periti P, Grassi GG, Eds. Current Chemotherapy and Immunotherapy: Proceedings of the 12th International Congress of Chemotherapy, Florence, Italy. Washington, DC: American Society for Microbiology, pp1210-1211, 1982.
57. Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Ito I, Ogawa N. End point result of a randomized controlled study on the treatment of gastrointestinal cancer with a combination of lentinan and chemotherapeutic agents. In: Proceedings of the 6th Symposium on Rationale of Biological Response Modifiers in Cancer Treatments, Hakone-machi, Japan, 1984. Amsterdam; Princeton, NJ: Excerpta Medica, pp151-165, 1985.
58. Fujimoto S, Furue H, Kimura T, Kondo T, Orita K, Taguchi T, Yoshida K, Ogawa N. Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer: A randomized controlled trial. Jpn J Surg 14:286-292, 1984.
59. Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukuda T, Goto S, Ichinohe K, Jimi S, Kasamatsu T, Kawai N, Mizuguchi K, Mori S, Nakano H, Noda K, Sekiba K, Suzuki K, Suzuki T, Takahashi K, Takeuchi K, Yajima A, Ogawa N. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study. Cancer 58:865-872, 1986.
60. Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukuda T, Goto S, Ichinohe K, Jimi S, Kasamatsu T, Kawai N, Mizuguchi K, Mori S, Nakano H, Noda K, Sekiba K, Suzuki K, Suzuki T, Takahashi K, Takeuchi K, Yajima A, Ogawa N. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy 1:103-107, 1989.
61. Kimura Y, Tojima H, Fukase S, Takeda K. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol Suppl (Stockh) 511:192-195, 1994.
62. Miyakoshi H, Aoki T, Mizukoshi M. Acting mechanism of Lentinan in human - II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon inducer. Int J Immunopharmacol 6:373-379, 1984.
63. Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Nagamatsu M, Hiroaki U, Akiyoshi T. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 14:535-539, 1992.
64. Arinaga S, Karimine N, Takamuku K, Nanbara S, Nagamatsu M, Ueo H, Akiyoshi T. Enhanced production of interleukin 1 and tumor necrosis factor by peripheral monocytes after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 14:43-47, 1992.
65. Matsuoka H, Yano K, Seo Y, Saito T, Tomoda H, Tsurumoto S. Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan. Anticancer Res 15:2291-2296, 1995.
66. Matsuoka H, Seo Y, Wakasugi H, Saito T, Tomoda H. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res 17:2751-2756, 1997.
67. Takeshita K, Watanuki S, Iida M, Saito N, Maruyama M, Sunagawa M, Habu H, Endo M. Effect of lentinan on lymphocyte subsets of peripheral blood, lymph nodes, and tumor tissues in patients with gastric cancer. Surg Today 23:125-129, 1993.
68. +) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival. Gynecol Oncol 56:412-420, 1995.
69. Nakano T, Oka K, Hanba K, Morita S. Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer. Clin Immunol Immunopathol 79:79-86, 1996.
70. Maeda YY, Chihara G, Ishimura K. Unique increase of serum proteins and action of antitumor polysaccharides. Nature 252:250-252, 1974.
71. Manabe T, Takahashi Y, Okuyama T, Maeda YY, Chihara G. Identification of mouse serum proteins increased by the administration of antitumor polysaccharide lentinan, by micro two-dimensional electrophoresis. Electrophoresis 4:242-246, 1983.
72. Nono I, Ohno N, Ohsawa M, Oikawa S, Yadomae T. Modification of immunostimulating activities of grifolan by the treatment with (1→3)-β-D-glucanase. J Pharmacobio-Dyn 12:671-680, 1989.
73. Maeda YY, Watanabe ST, Chihara G, Rokutanda M. T-cell mediated vascular dilatation and hemorrhage induced by antitumor polysaccharides. Int J Immunopharmacol 6:493-501, 1984.
74. Takatsuki F, Namiki R, Kikuchi T, Suzuki M, Hamuro J. Lentinan augments skin reaction induced by bradykinin: Its correlation with vascular dilatation and hemorrhage responses and antitumor activities. Int J Immunopharmacol 17:465-474, 1995.
75. Z‡k‡ny J, Chihara G, Fachet J. Effect of lentinan on tumor growth in murine allogeneic and syngeneic hosts. Int J Cancer 25:371-376, 1980.
76. Suga T, Shiio T, Maeda YY, Chihara G. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 44:5132-5137, 1984.
77. Maeda YY, Sakaizumi M, Moriwaki K, Yonekawa H. Genetic control of the expression of two biological activities of an antitumor polysaccharide, lentinan. Int J Immunopharmacol 13:977-986, 1991.
78. Maeda YY, Sakaizumi M, Moriwaki K, Chihara G, Yonekawa H. Genetical control on lentinan-induced acute phase responses and vascular responses. Folia Histochem Cytobiol 30:207-210, 1992.
79. Maeda YY, Takahama S, Kohara Y, Yonekawa H. Two genes controlling acute phase responses by the antitumor polysaccharide, lentinan. Immunogenetics 43:215-219, 1996.
80. Maeda YY, Takahama S, Kohara Y, Yonekawa H. Polygenic control of the expression of biological activities of an antitumor polysaccharide, lentinan. Int J Immunopharmacol 19:469-472, 1997.
81. Bluhm TL, Sarco A. The triple helical structure of lentinan, a linear β-(1→3)-d-glucan. Can J Chem 55:293-299, 1977.
82. Maeda YY, Watanabe ST, Chihara C, Rokutanda M. Denaturation and renaturation of a β-1,6;1,3-glucan, lentinan, associated with expression of T-cell-mediated responses. Cancer Res 48:671-675, 1988.
83. Yanaki T, Ito W, Tabata K, Kojima T, Norizuye T, Takano N, Fujita H. Correlation between the antitumor activity of a polysaccharide schizophyllan and its triple-helical conformation in dilute aqueous solution. Biophys Chem 17:337-342, 1983.
84. Okazaki M, Adachi Y, Ohno N, Yadomae T. Structure-activity relationship of (1→3)-β-D-glucans in the induction of cytokine production from macrophages, in vitro. Biol Pharm Bull 18:1320-1327, 1995.
85. Nono I, Ohno N, Ohsawa M, Oikawa S, Yadomae T. Modulation of antitumor activity of grifolan by subsequent administration of (1→3)-β-D-glucanase in vivo. J Pharmacobio-Dyn 12:581-588, 1989.
86. O'Hara Y. Fate of lentinan (antitumor polysaccharide) I: Fate of lentinan in mice, rats, and dogs. J Toxicol Sci 5:59-72, 1980.
87. O'Hara Y. Fate of lentinan (antitumor polysaccharide) II: Fate of methyl lentinan in rats. J Toxicol Sci 5:73-80, 1980.
88. Suda M, Ohno N, Adachi Y, Yadomae T. Tissue distribution of intraperitoneally administered (1→3)-β-D-Glucan (SSG), a highly branched antitumor glucan, in mice. J Pharmacobio-Dyn 15:417-426, 1992.
89. Suda M, Ohno N, Hashimoto T, Koizumi K, Adachi Y, Yadomae T. Kupffer cells play important roles in the metabolic degradation of a soluble antitumor (1→3)-β-D glucan, SSG, in mice. FEMS Immunol Med Microbiol 15:93-100, 1996.
90. Miura T, Ohno N, Suda M, Miura NN, Shimada S, Yadomae T. Inactivation of (1→3)-β-D-glucan in mice. Biol Pharm Bull 18:1797-1801, 1995.
91. Czop JK, Austen KF. A β-glucan inhibitable receptor on human monocytes: Its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J Immunol 134:2588-2593, 1985.
92. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement 4:61-74, 1987.
93. Janusz MJ, Austen KF, Czop JK. Lysosomal enzyme release from human monocytes by paniculate activators is mediated by β-glucan inhibitable receptors. J Immunol 138:3897-3901, 1987.
94. Sakurai T, Suzuki I, Kinoshita A, Oikawa S, Masuda A, Ohsawa M, Yadomae T. Effect of intraperitoneally administered β-1,3-glucan, SSG, obtained from Sclerotinia sclerotiorum IFO 9395 on the functions of murine alveolar macrophages. Chem Pharm Bull 39:214-217, 1991.
95. Oka M, Hazama S, Suzuki M, Wang F, Wadamori K, Iizuka N, Takeda S, Akimoti Y, Ohba Y, Kajiwara K, Suga T, Suzuki T. In vitro and in vivo analysis of human leukocyte binding by the antitumor polysaccharide, lentinan. Int J Immunopharmacol 18:211-216, 1996.
96. Abel G, Czop JK. Stimulation of human monocyte β-glucan receptors by glucan particles induces production of TNF-α and IL-1β. Int J Immunopharmacol 14:1363-1373, 1992.
97. Adachi Y, Ohno N, Yadomae T. Inhibitory effect of β-glucan on zymosan-mediated hydrogen peroxide production by murine peritoneal macrophages in vitro. Biol Pharm Bull 16:462-467, 1993.
98. Ikekawa T. Enokitake, Flammulina velutipes: Host-mediated antitumor polysaccharides. Food Rev Int 11:203-206, 1995.
99. Mizuno T, Ohsawa K, Hagwara N, Kuboyama R. Fractionation and characterization of antitumor polysaccharides from Maitake, Grifola frondosa. Agric Biol Chem 50:1679-1688, 1986.
100. Suzuki I, Sakurai T, Hashimoto K, Oikawa S, Masuda A, Ohsawa M, Yadomae T. Inhibition of experimental pulmonary metastasis of Lewis lung carcinoma by orally administered β-glucan in mice. Chem Pharm Bull 39:1606-1608, 1991.
101. Morinaga H, Tazawa K, Tagoh H, Muraguchi A, Fujimaki M. An in vivo study of hepatic and splenic interleukin-1β mRNA expression following oral PSK or LEM administration. Jpn J Cancer Res 85:1298-1303, 1994.
102. Fujii T, Maeda H, Suzuki F, Ishida N. Isolation and characterization of a new antitumor polysaccharide, KS-2, extracted from culture mycelia of Lentinus edodes. J Antibiot 31:1079-1090, 1978.
103. Sabolovic D, Galoppin L. Effect of a protein bound polysaccharide (PS-K) on tumor development and infections in splenectomized rats and mice. Int J Immunopharmacol 8:41-46, 1986.
104. Yunoki S, Tanaka N, Hizuta A, Orita K. Enhancement of antitumor cytotoxicity of hepatic lymphocytes by oral administration of PSK. Int J Immunopharmacol 16:123-130, 1994.
105. Wu D, Han SN, Bronson RT, Smith DE, Meydani SN. Dietary supplementation with mushroom-derived protein-bound glucan does not enhance immune function in young and old mice. J Nutr 128:193-197, 1998.
106. Palmieri L, Conte A, Giovannini L, Lualdi P, Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneim-Forsch/Drug Res 40:319-323, 1990.
107. Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneim-Forsch/Drug Res 41:768-772, 1991.
108. Volpi N. Physico-chemical properties and the structure of dermatan sulfate fractions purified from plasma after oral administration in healthy human volunteers. Thromb Haemostasis 75:491-496, 1996.
109. Sasaki T, Takasuka N. Further study of the structure of lentinan, an antitumor polysaccharide from Lentinus edodes. Carbohydrate Res 47:99-104, 1976.
110. Norisuye T, Yanaki T, Fujita H. Triple helix of a Schizophyllum commune polysaccharide in aqueous solution. J Polym Sci Polym Phys Ed 18:547-558, 1980.
111. Yanaki T, Norisuye T, Fujita H. Triple helix of Schizophyllum commune polysaccharide in dilute solution. 3. Hydrodynamic properties in water. Macromolecules 13:1462-1466, 1980.
112. Ohno N, Suzuki I, Yadomae T. Structure and antitumor activity of a β-1,3-glucan isolated from the culture filtrate of Sclerotinia sclerotiorum IFO 9395. Chem Pharm Bull 34:1362-1365, 1986.
113. Ohno N, Yadomae T. Two different conformations of the antitumor β-d-glucan produced by Sclerotinia sclerotiorum IF09395. Carbohydrate Res 159:293-302, 1987.
114. Chihara G, Maeda Y, Hamuro J, Sasaki T, Fumiko F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing Nature 222:687-688, 1969.
115. Fachet J, Abel G, Erdei J, Josupova S, Chihara G. Effect of lentinan on different types of immune responses including anaphylactic shock. In: Urushizaki I, Aoki T, Tsubura E, Eds. Host Defense Mechanisms Against Cancer. Princeton, NJ: Excerpta Medica, pp183-I94, 1981.
116. Akiyama Y, Kashima S, Hayami T, Izawa M, Mitsugi K, Hamuro J. Immunological characteristics of antitumor polysaccharides, lentinan and its analogs, as immune adjuvants. In: Aoki T, Urushizaki I, Tsubura E, Eds. Manipulation of Host Defense Mechanisms. Princeton, NJ: Excerpta Medica, p 227-238, 1981.
117. Komatsu N, Okubo S, Kikumoto S, Kimura K, Saito G, Sakai S. Host-mediated antitumor action of schizophyllan, a glucan produced by Schizophyllum commune. Gann 60:137-144, 1969.
118. Ohno N, Hayashi M, lino K, Suzuki I, Oikawa S, Sato K, Suzuki Y, Yadomae T. Effect of glucans on the antitumor activity of grifolan. Chem Pharm Bull 34:2149-2154, 1986.
119. Suzuki I, Hashimoto K, Oikawa S, Sato K, Osawa M, Yadomae T. Antitumor and immunomodulating activities of a β-glucan obtained from liquid-cultured Grifola frondosa. Chem Pharm Bull 37:410-413, 1989.
120. Suzuki I, Hashimoto K, Yadomae T. The effects of a highly branched β-1,3-glucan, SSG, obtained from Sclerotinia sclerotiorum IFO 9395 on the growth of syngeneic tumors in mice. J Pharmacobio-Dyn 11:527-532, 1988.